All BIIB Content

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

April 7, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

April 1, 20261 min read

Biogen Inc (BIIB) FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 30, 20261 min read

Biogen Inc (BIIB) Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 29, 20261 min read

Biogen Inc (BIIB) Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 19, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

March 12, 20261 min read

Biogen Inc (BIIB) Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 11, 20261 min read

Biogen Inc (BIIB) The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 4, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

February 12, 20261 min read

Biogen Inc (BIIB) Biogen Announces Board Chair Transition

Biogen Inc (NASDAQ: BIIB) FY 2026 Management Update

February 11, 20261 min read